NCT04685265: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease |
|
|
| Completed | 1 | 70 | Europe | anle138b, Placebo | MODAG GmbH, Aptuit, Quotient Sciences, Nottingham University Hospitals NHS Trust | Parkinson Disease | 11/22 | 12/22 | | |
NCT05532358: A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) |
|
|
| Completed | 1 | 54 | Europe | anle138b (TEV-56286), Caffeine, Midazolam, Fluvoxamine, Fluvoxamine 100 mg QD for 5 days, TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine | MODAG GmbH, Aptuit, Quotient Sciences, Teva Pharmaceutical Industries, Ltd. | Healthy Volunteers | 01/23 | 02/23 | | |